{"log_id": 5095940352836842034, "direction": 0, "words_result_num": 33, "words_result": [{"probability": {"variance": 0, "average": 0.999448, "min": 0.997005}, "location": {"width": 882, "top": 246, "height": 32, "left": 200}, "words": "相关的不良事件(参见【不良反应】),某些病例中有头皮痛、窦性心动过速(心电"}, {"probability": {"variance": 0.000459, "average": 0.992837, "min": 0.913449}, "location": {"width": 341, "top": 295, "height": 29, "left": 200}, "words": "图其他方面正常)和/或粘膜炎症"}, {"probability": {"variance": 0, "average": 0.999846, "min": 0.999797}, "location": {"width": 46, "top": 344, "height": 27, "left": 202}, "words": "治疗"}, {"probability": {"variance": 1e-06, "average": 0.999322, "min": 0.99681}, "location": {"width": 849, "top": 385, "height": 30, "left": 235}, "words": "本品主要不经肾排泄,其血浆白蛋白的结合率很高,因此预计血液透析不能有效增"}, {"probability": {"variance": 0.000144, "average": 0.993554, "min": 0.966727}, "location": {"width": 142, "top": 435, "height": 27, "left": 199}, "words": "加本品的清除"}, {"probability": {"variance": 3e-06, "average": 0.999148, "min": 0.992811}, "location": {"width": 749, "top": 477, "height": 31, "left": 234}, "words": "进一步的治疗应当根据临床情况或当地毒物控制中心(如有)的建议进行"}, {"probability": {"variance": 1.4e-05, "average": 0.996242, "min": 0.991452}, "location": {"width": 147, "top": 580, "height": 31, "left": 211}, "words": "【临床试验】"}, {"probability": {"variance": 3e-06, "average": 0.998913, "min": 0.993294}, "location": {"width": 283, "top": 643, "height": 30, "left": 201}, "words": "拉帕替尼联合卡培他滨治疗"}, {"probability": {"variance": 0, "average": 0.944629, "min": 0.944629}, "location": {"width": 104, "top": 647, "height": 43, "left": 887}, "words": "月"}, {"probability": {"variance": 0.000303, "average": 0.994192, "min": 0.911977}, "location": {"width": 835, "top": 695, "height": 29, "left": 248}, "words": "在一项随机、开放、对照试验中(EGF100151试验)对本品联合卡培他滨治疗乳腺"}, {"probability": {"variance": 0.000192, "average": 0.995842, "min": 0.921959}, "location": {"width": 884, "top": 737, "height": 35, "left": 200}, "words": "癌的疗效和安全性进行了评价。参加研究的患者需要符合的条件是:ErbB2过表达"}, {"probability": {"variance": 0.003224, "average": 0.978462, "min": 0.739779}, "location": {"width": 873, "top": 785, "height": 30, "left": 213}, "words": "(IHC++或经FISH证实过的IHC++)、局部晚期或转移性乳腺癌、既往接受过紫杉"}, {"probability": {"variance": 5e-06, "average": 0.998607, "min": 0.990087}, "location": {"width": 468, "top": 834, "height": 29, "left": 203}, "words": "类、蒽环类和曲妥珠单抗治疗后出现疾病进展"}, {"probability": {"variance": 4.8e-05, "average": 0.997525, "min": 0.959605}, "location": {"width": 836, "top": 878, "height": 30, "left": 249}, "words": "患者随机分为2组,一组用本品1250mg,每天1次(持续应用)联合卡培他滨"}, {"probability": {"variance": 0.000296, "average": 0.993812, "min": 0.918078}, "location": {"width": 867, "top": 924, "height": 28, "left": 216}, "words": "2000mg/m2/天第1-14天,每21天1个周期),另一组卡培他滨单药治疗(2500"}, {"probability": {"variance": 0.001296, "average": 0.991087, "min": 0.774711}, "location": {"width": 871, "top": 969, "height": 29, "left": 212}, "words": "g/m2/天第1-14天,每21天1个周期)。研究治疗持续至疾病进展或因其他原因退"}, {"probability": {"variance": 1e-06, "average": 0.999238, "min": 0.993239}, "location": {"width": 883, "top": 1015, "height": 30, "left": 203}, "words": "出。主要终点为至肿瘤进展时间(TTP),定义为从随机化至出现肿瘤进展或乳腺癌相"}, {"probability": {"variance": 2.5e-05, "average": 0.998122, "min": 0.970421}, "location": {"width": 881, "top": 1060, "height": 30, "left": 204}, "words": "关死亡的时间。根据预先设定的中期分析结果,停止了病例入选。399例患者参加了这"}, {"probability": {"variance": 4.2e-05, "average": 0.996325, "min": 0.973354}, "location": {"width": 678, "top": 1107, "height": 29, "left": 203}, "words": "项研究。患者的中位年龄为53岁,14%患者大于65岁。91%患者"}, {"probability": {"variance": 0.000272, "average": 0.987537, "min": 0.964202}, "location": {"width": 71, "top": 1108, "height": 27, "left": 1015}, "words": "患者为"}, {"probability": {"variance": 0, "average": 0.912753, "min": 0.912753}, "location": {"width": 21, "top": 1133, "height": 21, "left": 889}, "words": " GU"}, {"probability": {"variance": 0.010319, "average": 0.948724, "min": 0.594317}, "location": {"width": 842, "top": 1142, "height": 56, "left": 203}, "words": "Ⅳ期乳腺癌,48%为雌激素受体阳性(ER阳性)或孕激素受体注润"}, {"probability": {"variance": 0.036503, "average": 0.863403, "min": 0.410186}, "location": {"width": 875, "top": 1191, "height": 45, "left": 202}, "words": "患者为ErbB2IHC+1+1或HCH1(经FISH证实)。大约药过"}, {"probability": {"variance": 1e-06, "average": 0.999437, "min": 0.997125}, "location": {"width": 306, "top": 1244, "height": 29, "left": 202}, "words": "类、紫杉类和曲妥珠单抗治疗"}, {"probability": {"variance": 8e-06, "average": 0.964927, "min": 0.962027}, "location": {"width": 88, "top": 1251, "height": 29, "left": 936}, "words": "米1"}, {"probability": {"variance": 4e-06, "average": 0.998928, "min": 0.990506}, "location": {"width": 753, "top": 1287, "height": 31, "left": 249}, "words": "在中期分析4个月后进行了后续有效性分析,结果详见表10、图1和图2"}, {"probability": {"variance": 3e-05, "average": 0.996223, "min": 0.979424}, "location": {"width": 635, "top": 1334, "height": 29, "left": 204}, "words": "表10EGF100151研究的关键疗效数据(截止2006年4月3日)"}, {"probability": {"variance": 1e-06, "average": 0.998848, "min": 0.996459}, "location": {"width": 118, "top": 1379, "height": 25, "left": 384}, "words": "独立数据评估"}, {"probability": {"variance": 5e-06, "average": 0.998045, "min": 0.994137}, "location": {"width": 100, "top": 1378, "height": 24, "left": 746}, "words": "研究者评估"}, {"probability": {"variance": 1e-06, "average": 0.998887, "min": 0.997327}, "location": {"width": 87, "top": 1418, "height": 25, "left": 382}, "words": "拉帕替尼"}, {"probability": {"variance": 0.000331, "average": 0.990496, "min": 0.913008}, "location": {"width": 484, "top": 1417, "height": 26, "left": 565}, "words": "卡培他滨2000mg拉帕替尼1250mg/卡培他滨200"}, {"probability": {"variance": 0.026958, "average": 0.911281, "min": 0.517215}, "location": {"width": 235, "top": 1456, "height": 26, "left": 385}, "words": "日十卡培他滨/m/日"}, {"probability": {"variance": 0.019984, "average": 0.904083, "min": 0.590578}, "location": {"width": 235, "top": 1456, "height": 25, "left": 748}, "words": "日+卡培他滨/m2/日"}], "language": 3}